FDA cited a firm for resuming sterile filling after a 5-week shutdown without conducting a media fill to validate the aseptic line. According to industry guidance for sterile drug manufacturing, aseptic processes need to be revalidated after extended shutdowns, equipment changes, or environmental disruptions.
The 483 reads as follows:
“Your firm failed to conduct aseptic process simulation (media fill)… after a shutdown period. The line was declassified for 5 weeks… [and] your firm resumed the filling activities… and released three (3) lots… prior to the next media fill, which was conducted 6 weeks after production resumed.”
In this particular case, the shutdown involved preventive maintenance on the filler, re-certification of HEPA filters, and floor repair, which are all potential contaminants or process disruptors. Wrongly, production resumed and product was released before the next media fill, effectively skipping the requalification step.
This observation strikes at the heart of sterile manufacturing fundamentals: if you don’t validate aseptic conditions, you cannot assume product sterility.
Skipping media fill validation in such a scenario introduces an unquantified risk of microbial contamination. FDA guidance makes it clear that media fills must simulate actual production conditions: “A media fill should be repeated whenever aseptic operations are modified or replaced in a manner that could affect the original state of validation.”
FDA guidance for Sterile Drug Products Produced by Aseptic Processing is linked here. The related CFR citation, 21 CFR §211.113(b), is linked here.
